Canada markets closed
  • S&P/TSX

    20,928.10
    +108.16 (+0.52%)
     
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • DOW

    35,294.76
    +382.20 (+1.09%)
     
  • CAD/USD

    0.8086
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    82.66
    +1.35 (+1.66%)
     
  • BTC-CAD

    75,629.04
    +1,109.20 (+1.49%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • GOLD FUTURES

    1,768.10
    -29.80 (-1.66%)
     
  • RUSSELL 2000

    2,265.65
    -8.52 (-0.37%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • NASDAQ

    14,897.34
    +73.91 (+0.50%)
     
  • VOLATILITY

    16.30
    -0.56 (-3.32%)
     
  • FTSE

    7,234.03
    +26.32 (+0.37%)
     
  • NIKKEI 225

    29,068.63
    +517.70 (+1.81%)
     
  • CAD/EUR

    0.6966
    -0.0001 (-0.01%)
     
LATEST UPDATE:

NO WEEKLY BRIEF NEWSLETTER FOR THE WEEKEND OF OCT. 16-17

Caraway Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

·2 min read

CAMBRIDGE, Mass., September 16, 2021--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Thursday, September 23, 2021 at 2:55pm Eastern Time. The presentation will cover recent progress from Caraway’s lead program targeting modulation of the lysosomal cation channel, TRPML1, for GBA-Parkinson’s disease and other rare diseases, and highlight the recently established collaboration with AbbVie on Caraway’s second program targeting the lysosomal potassium channel, TMEM175, for Parkinson’s and other neurodegenerative diseases.

"I look forward to sharing updates on Caraway’s promising programs at the Oppenheimer healthcare fall summit," said Williams. "We have made substantial progress on our approach that combines genetically defined targets and our expertise in lysosomal biology to develop oral small molecule therapeutics to address unmet medical needs in neurodegenerative and rare diseases."

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005192/en/

Contacts

Media Contact:
MacDougall
Kari Watson or Nicholas Chang
(781) 235-3060
kwatson@macbiocom.com or nchang@macbiocom.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting